Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses
- PMID: 28902983
- DOI: 10.1002/mabi.201700187
Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses
Abstract
Oncolytic viruses (OVs) are novel anticancer agents that combine direct cancer cell killing with the stimulation of antitumor immunity. In addition, OVs can be engineered to deliver biological therapeutics directly to tumors, offering unique opportunities to design multimodal anticancer strategies. Here, a case for arming OVs with bispecific T cell engagers (BiTEs) is put forward. BiTEs redirect the cytotoxicity of polyclonal T cells to target cells of choice, and have demonstrated efficacy against a number of hematological cancers. However, the success of BiTEs in the treatment of solid tumors appears more limited, at least in part due to: (i) poor delivery kinetics and penetration into tumors, and (ii) on-target off-tumor activity, leading to dose-limiting toxicities. Linking the production of BiTEs to OV replication provides an exciting means to restrict production to the tumor site, widen their therapeutic window, and synergize with direct oncolysis. This review summarizes progress thus far in the preclinical development of BiTE-armed OVs, and explores the possibility of cotargeting cancer cells and nontransformed stromal cells.
Keywords: T cell therapy; Tumor microenvironment; bispecific T cell engagers; immunotherapy; oncolytic viruses.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status.Biochim Biophys Acta Mol Basis Dis. 2024 Feb;1870(2):166962. doi: 10.1016/j.bbadis.2023.166962. Epub 2023 Nov 19. Biochim Biophys Acta Mol Basis Dis. 2024. PMID: 37984801 Review.
-
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.J Hematol Oncol. 2021 Apr 16;14(1):63. doi: 10.1186/s13045-021-01075-5. J Hematol Oncol. 2021. PMID: 33863363 Free PMC article. Review.
-
Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.Clin Cancer Res. 2018 May 1;24(9):2128-2137. doi: 10.1158/1078-0432.CCR-17-2651. Epub 2018 Feb 6. Clin Cancer Res. 2018. PMID: 29437789
-
Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.Hum Gene Ther. 2018 Feb;29(2):151-159. doi: 10.1089/hum.2017.212. Hum Gene Ther. 2018. PMID: 29284308 Review.
-
Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.Front Immunol. 2024 Feb 22;15:1343378. doi: 10.3389/fimmu.2024.1343378. eCollection 2024. Front Immunol. 2024. PMID: 38464532 Free PMC article. Review.
Cited by
-
Cancer immunotherapies: A hope for the uncurable?Front Mol Med. 2023 Feb 17;3:1140977. doi: 10.3389/fmmed.2023.1140977. eCollection 2023. Front Mol Med. 2023. PMID: 39086690 Free PMC article. Review.
-
Please stand by: how oncolytic viruses impact bystander cells.Future Virol. 2018 Sep;13(9):671-680. doi: 10.2217/fvl-2018-0068. Epub 2018 Aug 8. Future Virol. 2018. PMID: 30416535 Free PMC article. Review.
-
Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment.Immunother Adv. 2023 Aug 10;3(1):ltad013. doi: 10.1093/immadv/ltad013. eCollection 2023. Immunother Adv. 2023. PMID: 37599903 Free PMC article. Review.
-
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.Mol Ther. 2018 Jun 6;26(6):1414-1422. doi: 10.1016/j.ymthe.2018.04.001. Epub 2018 Apr 5. Mol Ther. 2018. PMID: 29703699 Free PMC article. Review.
-
Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer.Int J Mol Sci. 2020 Sep 25;21(19):7073. doi: 10.3390/ijms21197073. Int J Mol Sci. 2020. PMID: 32992948 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
